Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
Date:10/30/2008

py with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

Poniard Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenues $- $- $- $-

Operating expenses:

Research and development 9,024 5,050 24,511 16,362

General and administrative 3,383 2,806 11,289 8,584

Total operating expenses 12,407 7,856 35,800 24,946

Loss from operations (12,407) (7,856) (35,800) (24,946)

Other income, net 170 897 1,177 1,730

Net loss (12,237) (6,959) (34,623) (23,216)

Preferred stock dividends (125) (125) (375) (375)

Net loss applicable to common

shares $(12,362) $(7,084) $(34,998) $(23,591)

Los
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 Cuidado Casero ... and hospice, PCO, PCA, and PHC in Texas, New Mexico, ... a sponsor of the North Texas Chapter of PAM’s 2014 ... the Peruvian American Medical Society. The North Texas chapter was ... and other professionals interested in improving medical care for the ...
(Date:7/27/2014)... 2014 Hyaluronic Acid can hold 1,000 ... key to the power of Hyaluronic Serums. , "Hyaluronic ... founder of Sublime Beauty®. "But like collagen, it diminishes ... ours improves skin moisture-retention and radiance." , Hyaluronic ... a healthy and beautiful look. Key Ingredients in the ...
(Date:7/27/2014)... Detroit, MI (PRWEB) July 27, 2014 ... the public with organic ways to achieve a younger ... eye cream buyer's guide to help men and women ... . , The details that are presented in the ... range of price information for consumers. On drawback to ...
(Date:7/27/2014)... new pill-only antiviral drug regimens could provide shorter, more ... majority of patients infected with hepatitis C, even those ... two studies published in The Lancet . , ... is the most common genotype in the USA, Europe, ... the most difficult to treat. , Around 150 million ...
(Date:7/27/2014)... a powerful drug given at the time of a ... of rejection, but that it also allows a less ... the operation. , The key results are reported in ... Transplant Congress in San Francisco today. They will help ... combinations of treatments used to prevent early kidney rejection ...
Breaking Medicine News(10 mins):Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3
... cause damage to the brain of youngsters, says a ... misuse can do to them. // ,Thomas Heffernan, ... students for the research presented at the British Psychological ... of Daily Mail. ,Half the students ...
... research team from the New York University College of Dentistry ... oral decay evolved along with its human hosts. ... common ancestor who lived in Africa between 100,000 and 200,000 ... by Page Caufield, a professor of cariology and comprehensive care ...
... in EMBO says that the parasite that is responsible ... new pathway. Sleeping sickness is caused by Trypanosoma brucei ... ,Shulamit Michaeli and colleagues describe a pathway in T. ... this pathway shuts down the synthesis of a crucial ...
... the healthcare sector with a super-specialty hospital in Gurgaon,// on ... of Rs.2.1 billion ($45 million). ,Christened Artemis Health ... will open next month. "In the second phase, another 240 ... of AHS. ,"This is the first of similar ...
... governments to join the anti-tuberculosis global plan, which would ... disease has become extremely drug-resistant. ,Ban's message ... on Saturday. The World Health Organization (WHO) recently reported ... of tuberculosis, XDR-TB, which threatens to derail efforts to ...
... be hampered if they indulge in excessive drinking.// This ... a psychologist from Northumbria University. ,Alcohol and ... young age which could extend into adulthood. According to ... a very crucial stage. ,Dr. Thomas Heffernan ...
Cached Medicine News:Health News:Tooth Decay Bacteria Evolved Along With Man 2
(Date:7/27/2014)... 2014 /PRNewswire-iReach/ -- This is a professional ... Chinese Vardenafil (CAS 224785-90-4) industry. The report ... (CAS 224785-90-4) including its classification, application and ... and China,s top manufacturers of Vardenafil (CAS ... value, cost, gross margin and market share ...
(Date:7/25/2014)... 25, 2014  Depomed, Inc. (NASDAQ: DEPO ... fiscal year 2014 financial results after the market closes ... conference call beginning at 4:30 pm EDT, 1:30 pm PDT to ... call by dialing 877-317-6789 ( United States ... be available via a live webcast on the investor ...
(Date:7/25/2014)... July 25, 2014  CVS Caremark Corporation (NYSE: ... on Tuesday, August 5, 2014, at 8:30 a.m. (EDT) ... 2014 financial results. An audio webcast of ... Investor Relations portion of the CVS Caremark website for ... http://info.cvscaremark.com/investors . This webcast will be archived and available ...
Breaking Medicine Technology:Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
... gamma imaging,(BSGI) is effective in the detection of cancers ... a study presented today at the annual meeting of,the ... "BSGI can identify the most ... Rachel F. Brem, M.D., professor of,radiology and director of ...
... Laboratories, a leading clinical-diagnostics and biomedical-research laboratory specializing ... launched two tests to evaluate the response ... to a primary immunodeficiency disorder, chemotherapy drugs, or because ... a transplant. The company launched the two new assays, ...
Cached Medicine Technology:New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: